Midodrine
As of the edition of 20 October 2026, Midodrine is a small molecule: marketed, first approved in 1992 (FR); acts on ADRA1A, ADRA1B and ADRA1D.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2002
- Kind
- Small molecule
- Brand name
- Proamatine
- First approved
- 16 June 1992 (FR)
- Approvals on record
- 5 in 3 regions
- Holder of the most recent approval
- Cheplapharm Arzneimittel; 3 holders in all
- Registered trials
- 62, 10 stopped early
- Disease areas
- Heart and blood vessels; Nervous system; Digestive system; Injuries; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product3 company-target rows are on route B because of Midodrine.
See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 19 | 8 | 2 | 4 |
| Phase 1 | 8 | 7 | 1 | 0 |
| Phase 2 | 12 | 8 | 2 | 1 |
| Phase 3 | 10 | 6 | 1 | 3 |
| Phase 4 | 13 | 8 | 2 | 2 |
| All trials | 62 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Takeda | Acquired holder and Lead sponsor of trials | 1997 to now |